Exclusive weekly insights for sharemarket success.
Each week join Kien Trinh, Head of Research, and his team as they discuss all things sharemarket.
Tim Lincoln, Co-Founder and Chief Investment Officer, and Matt Swartz, Senior Portfolio Manager, will join the conversation once a month to share their passion and strategy for Lincoln Indicator’s Managed Funds, as well as their insights for investors.
In this edition of Taking Stock, Co-Founder, Executive Chairman and Chief Investment Officer Tim Lincoln and Head of Research Kien Trinh discuss the reasons for the strong performance of the Lincoln Australian Growth Fund. They highlight the bank reporting season and provide options for income investors who have been disappointed with the deferral/reduction in bank dividends. They also explain why IAG Australia Group (IAG) may have to reduce its dividends despite the company retaining its guidance. Resmed (RMD) is the stock under the microscope and the question of the week is “what is quantitative easing?”
Experience Stock Doctor yourself by taking a FREE trial today.
To discuss the future of your investments in detail, book in a free consultation with a Lincoln representative.
To discuss the future of your investments in detail, book in a free consultation with a Lincoln financial expert.